MRM Proteomics and Biodesix Partner to Develop Precision Lung Cancer Diagnostics
MONTREAL and BOULDER, Colo., Jan. 28, 2018 (BUSINESS WIRE) MRM Proteomics Inc. and Biodesix® have inked a partnership to create novel assays to answer critical clinical questions within the lung cancer continuum of care. Under terms of the deal, MRM Proteomics will grant Biodesix rights to utilize its proprietary iMALDI technologies to further advance its blood-based lung cancer diagnostics. Both companies share a commitment to advancing precision medicine’s accuracy and accessibility to cancer patients.
“Examining a patient’s genomic data has advanced targeted therapies. However, proteins are the targets of most drugs and hold the key to unlocking the promise of precision medicine,” said Christoph Borchers, CSO for MRM Proteomics. “Biodesix is a natural partner for our proteomic technology, because they are committed to a multi-omics approach to reveal a more complete molecular profile of lung cancer in the body. We believe that this partnership will produce much-needed advances in the proteomic space and lead to more precise lung cancer diagnostic tools that can help guide treatment decisions.”
Lung cancer is a leading cause of cancer deaths worldwide. The ability to diagnose cancer at an early stage can improve overall survival rates; the ability to rule out cancer for those at risk can reduce patient anxiety and unnecessary procedures. Precision diagnostic tools are needed to give patients and clinicians accurate, timely information. The MRM Proteomics / Biodesix partnership underscores the role of proteomics in delivering these tools.
“Elevating the importance of proteomics in revealing the full complexity of cancer is critical to getting patients the right treatment at the right time. MRM Proteomics is a leader in providing technologies that can help us unleash this potential,” said Scott Hutton, COO for Biodesix.
Learn how proteomic profiling reveals the real-time complexity of disease and the immune response by visiting here.
Topics: Press Releases